BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33846813)

  • 1. Celastrol attenuates the inflammatory response by inhibiting IL‑1β expression in triple‑negative breast cancer cells.
    You D; Jeong Y; Yoon SY; A Kim S; Kim SW; Nam SJ; Lee JE; Kim S
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Tumour Biol; 2016 Apr; 37(4):4991-9. PubMed ID: 26537583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celastrol Inhibits Migration and Invasion of Triple-Negative Breast Cancer Cells by Suppressing Interleukin-6 via Downregulating Nuclear Factor-κB (NF-κB).
    Yan F; Wu Z; Li Z; Liu L
    Med Sci Monit; 2020 Sep; 26():e922814. PubMed ID: 32920591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COL8A1 enhances the invasion/metastasis in MDA-MB-231 cells via the induction of IL1B and MMP1 expression.
    Sagara A; Miura S; Kobinata A; Naganawa R; Yaginuma S; Saito S; Saito R; Kominato H; Yumoto T; Sato F
    Biochem Biophys Res Commun; 2023 Jan; 642():145-153. PubMed ID: 36577251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next‑generation sequencing analysis reveals that MTH‑3, a novel curcuminoid derivative, suppresses the invasion of MDA‑MB‑231 triple‑negative breast adenocarcinoma cells.
    Chiu YJ; Tsai FJ; Bau DT; Chang LC; Hsieh MT; Lu CC; Kuo SC; Yang JS
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticles based on polymers modified with pH-sensitive molecular switch and low molecular weight heparin carrying Celastrol and ferrocene for breast cancer treatment.
    Qian Y; Zhang J; Xu R; Li Q; Shen Q; Zhu G
    Int J Biol Macromol; 2021 Jul; 183():2215-2226. PubMed ID: 34097964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celastrol inhibit the proliferation, invasion and migration of human cervical HeLa cancer cells through down-regulation of MMP-2 and MMP-9.
    Zhang J; Wang R; Cheng L; Xu H
    J Cell Mol Med; 2021 Jun; 25(11):5335-5338. PubMed ID: 33945201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated STC‑1 augments the invasiveness of triple‑negative breast cancer cells through activation of the JNK/c‑Jun signaling pathway.
    Han J; Jeon M; Shin I; Kim S
    Oncol Rep; 2016 Sep; 36(3):1764-71. PubMed ID: 27459971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphenol A Increases the Migration and Invasion of Triple-Negative Breast Cancer Cells via Oestrogen-related Receptor Gamma.
    Zhang XL; Liu N; Weng SF; Wang HS
    Basic Clin Pharmacol Toxicol; 2016 Oct; 119(4):389-95. PubMed ID: 27038254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.
    Liu W; Xiong X; Chen W; Li X; Hua X; Liu Z; Zhang Z
    Int J Oncol; 2020 Aug; 57(2):488-499. PubMed ID: 32626933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
    Front Immunol; 2019; 10():804. PubMed ID: 31105691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entelon
    You D; Jeong Y; Yoon SY; Kim SA; Lo E; Kim SW; Lee JE; Nam SJ; Kim S
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34203721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celastrol inhibits breast cancer cell invasion via suppression of NF-ĸB-mediated matrix metalloproteinase-9 expression.
    Kim Y; Kang H; Jang SW; Ko J
    Cell Physiol Biochem; 2011; 28(2):175-84. PubMed ID: 21865725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast Cancer Cell-Derived Soluble CD44 Promotes Tumor Progression by Triggering Macrophage IL1β Production.
    Jang JH; Kim DH; Lim JM; Lee JW; Jeong SJ; Kim KP; Surh YJ
    Cancer Res; 2020 Mar; 80(6):1342-1356. PubMed ID: 31969374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression.
    Lim JP; Nair S; Shyamasundar S; Chua PJ; Muniasamy U; Matsumoto K; Gunaratne J; Bay BH
    Cancer Lett; 2019 Jun; 452():119-131. PubMed ID: 30905819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone.
    Jeon M; Han J; Nam SJ; Lee JE; Kim S
    Chem Biol Interact; 2016 Oct; 258():126-33. PubMed ID: 27567548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.